Ask The Board

  1. As Governments Develop Policies And Regulatory Guidelines Around AI, What Advice Do You Have For Pharma Leaders On AI Implementation?

    See the answer from David Pyott, the chairman of Bioniz Therapeutics, a biopharma startup in Irvine, CA. He is the former CEO of Allergan.

  2. What Role Should The Pain Therapeutics Industry Play In Combatting The Opioid Epidemic?

    See the answer from Mitchell Katz, Ph.D., who has 30 years’ experience in the pharma and biotech. He is VP of development operations at Ferring Pharmaceuticals.

  3. How Do You View The Emerging Field Of Anti-Aging Therapies? Is This Therapeutic Approach Ready Now, Five Years Away, Or A Pipe Dream?

    See the answer from Sesha Neervannan, Ph.D., SVP of pharmaceutical development at Allergan.

  4. Over The Next Few Years, Should Biopharmas Broaden Their Definition For What They Define As “Core?”

    See the answer from Joseph Ferra, CFO of Syros Pharmaceuticals.

  5. What Are Some Of The Key Components In Gaining FDA Fast Track Designation For A Therapeutic?

    See the answer from Leslie Williams, president, CEO, and founder of ImmusanT, Inc.

  6. There Are Some Trends We Know To Expect, But What’s A Trend You Fear May Be Being Overlooked?

    See the answer from John Crowley, the chairman and CEO of Amicus Therapeutics.

  7. Are You Seeing Any Initiatives By The Industry To Adopt The “Public” Blockchain For This And/Or Similar Purposes?

    See the answer from Craig Lipset, head of clinical innovation within worldwide R&D at Pfizer.

  8. How Will IT Applications Used In R&D And Manufacturing Change To Meet The New Requirements Associated With Gene Therapy? What New Functionality Will Need To Be Provided?

    See the answer from John Reynders is VP, R&D strategy, program management, and data sciences at Alexion.

  9. Regarding Clinical Trial Matching Services, How Mature Is This Technology? What Should I Be Looking For If I Want To Use These Services, And Do They Work Well In All Therapeutic Areas?

    See the answer from Mary Rose Keller is VP clinical operations at Heron Therapeutics.

  10. Should We Be Thinking About The Ethical Considerations Of Approving Clinical Trials Based On Scientific Merit/Patient Safety When 30 Percent Of Trials Will Never Complete Enrollment? Are We Breaking Our Commitment To Patients?

    See the answer from John LaMattina, Ph.D., the former senior VP at Pfizer, Inc. and president of Pfizer Global R&D.